Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432088 | 0.86 | MAPK1 (0.44) | MAPK1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL1430708 | 0.85 | — | — | |
| SCHEMBL3433273 | 0.85 | GCK (0.44) | MAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3433064 | 0.85 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL3431725 | 0.85 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL3434320 | 0.84 | NPC1 (0.47) | MAPK1NPC1ATG4B | |
| SCHEMBL3434663 | 0.81 | RAB9A (0.38) | NPC1RAB9ALMNASMN1; SMN2MAPT | |
| SCHEMBL3434314 | 0.80 | TRPV1 (0.40) | MAPK1 | |
| SCHEMBL1430243 | 0.79 | — | — | |
| SCHEMBL3434335 | 0.78 | CYP2A6 (0.44) | MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | MAPK1 2843/4885NPC1 1917/4885RAB9A 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.